HIV and AIDS management in Italy: critical issues

Slides:



Advertisements
Similar presentations
HIV & TB. Worldwide TB is the most important opportunistic infection in HIV patients – its the commonest killer. Around 20 million people worldwide are.
Advertisements

PEPFAR Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins, B.
CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS Stephen J. Gluckman, M.D. Botswana-UPENN Partnership.
VIRAL ENCEPHALITIS A range of viruses can cause encephalitis but only a minority of patients have a history of recent viral infection. In Europe, the most.
Case Discussion: Complications after ART Weerawat Manosuthi, MD Department of Medicine Bamrasnaradura Infectious Diseases Institute, Ministry of Public.
Autopsies in HIV: still finding missed diagnoses after 20 years Background Mortality has significantly fallen with the advent of HAART and chemoprophylaxis.
Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
TUBERCULOSIS IN THE AGE OF HIV Dr. Terry Baker Physician National Chest Hospital.
IAS–USA When to Start Antiretroviral Therapy Constance A. Benson, MD Professor of Medicine University of California San Diego FINAL: Presented.
Cryptococcal Meningitis Dr N Thumbiran Infectious Diseases Department UKZN.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
1 Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.
Quize of the week Hajer AlZuhair Medical resident.
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
Mary Lawrence Hicks, FNP Positive Health Program October 21, 2010.
Immune Reconstitution Inflammatory Syndrome (IRIS)
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER ART Initiation in Resource-Limited Settings Susan M. Graham Assistant Professor, Medicine and Global.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,
TB-H V Co-infection by Dr. Ker Hong Bee 11. LEARNING OBJECTIVES To know & understand about TB-HIV co- infection in relation to:- – interaction & prevalence.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.
A randomized study of tenofovir containing HAART compared to lamivudine containing HAART in antiretroviral naïve HIV/HBV coinfected patients in Thailand:
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Novel Antiretroviral Studies and Strategies
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
Switch from TDF to TAF GS-US Study GS-US Study
J. Khan, MD, Y. Baraki, MD, J. Mallalieu, DO, MD, M
Comparison of INSTI vs INSTI
undetectable (undetectable-6.25)
Toxoplasma Encephalitis in Patients Infected with HIV & AIDS
1.
Indeterminate and inconclusive results are common when using Interferon Gamma Release Assay as screening for TB in patients with IBD Nasr I, Goel RM, Ward.
Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.
ART and toxicities: CNS
Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.
CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS
Dr Dawood Quiz questions.
Intensification with INSTI
VACS Polypharmacy Workgroup
Saquinavir + RTV versus Lopinavir-RTV in Treatment-Naïve GEMINI Trial
Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.
PHARMACOTHERAPY III PHCY 510
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Countless mycobacteria inside a macrophage
Cryptococcal Immune Reconstitution Inflammatory Syndrome
Cryptococcosis: Epidemiology of cryptococcal disease
Cryptococcal Immune Reconstitution Inflammatory Syndrome
Cryptococcosis: Epidemiology of cryptococcal disease
Comparison of NNRTI vs PI/r
Anthony D Harries Ministry of Health, Malawi
Comparison of NNRTI vs NNRTI
CASO CLINICO Il paziente naϊve ad alta viremia.
Comparison of INSTI vs INSTI
Comparison of PI vs PI ATV vs ATV/r BMS 089
CASO CLINICO Il paziente naϊve con resistenze al basale.
Switch to DTG-containing regimen
Sequencing cohorts Open-label Design W8 W12 ≥ 18 years
Presentation transcript:

HIV and AIDS management in Italy: critical issues 1. Late and AIDS presenters 2. Costs-effectiveness management 3. Antiretroviral long term toxicties 4. HCV- and HBV-coinfections 5. Non AIDS-defining malignancies

1. Late and AIDS presenters in Italy According to recent surveys, more or less one third of HIV diagnosis involve subjects with CD4 cell counts lower than 200 cells/mL 20% of HIV diagnosis are performed in the setting of an opportunistic infection Age, male gender and not Caucasian ethnicity are often associated with a later presentation of HIV infection Borghi V, J Acquir Immune Defic Syndr 2008

AIDS presenters: clinical outcome Possible normalization of CD4 cell count still with low baseline counts (Mocroft, Lancet, 2007) Slower immunoreconstitution if low baseline counts (Kaufmann, Clin Infect Dis 2005) Among AIDS presenter idividuals mortality rate are significant also in the HAART era Mussini C, Manzardo C, Johnson M, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22: 2461-2469

2. Costs-effectiveness management in Italy E.G.: Lumbardy region “Piano diagnostico-terapeutico” “If there are several ARV regimens which are expected to have similar outcomes, choose the cheapest one” “Changes to more expensive regimens are advisable only in case of severe toxicities”

Case presentation (November 2010) Male patient, 61 years-old; hypertension in therapy; good health until three weeks before Access to Emergency Department for: fever and a progressive alteration of consciousness Not any deficit at the phisical examination (not even rigor nucalis) Increase of C reactive protein and of the eritrocite sedimentation rate with a slight anaemia HIV-ELISA positive, a tuberculin intra-dermal reaction positive (5 UI, 48 hours) CD4+71 cells/mL, HIV-RNA 418,130 copies/mL (homosexual risk factor) Lumbar puncture: 20 white blood cells (lymphocytes), low glucose and high protein Ziehl-Neelsen coloration for mycobacteria and other opportunistic agents were negative A therapy for a Tuberculosis meningitis was begun PCR for Mycobacterium tuberculosis resulted to be positive

Therapy and immuno-virological outcome 100 200 300 400 500 600 700 800 nov-10 jan-11 feb-11 apr-11 jun-11 ago-11 oct-11 CD4 (cells/m L) 1 2 3 4 5 6 HIV-RNA (Log copies/mL) CD4 HIV-RNA ISONIAZIDE RIFAMPICIN ETHAMBUTOL PYRAZINAMIDE AZT ABC + 3TC + RAL TDF + FTC + EFV 935 euros/month 919 euros/month 653 euros/month

Presentation of RECURRENT SCOTOMA During the follow up… (November 2012) Presentation of RECURRENT SCOTOMA Normal physical examination and blood analysis Normal funduscopic examination and visual acuity Normal blood pressure Several frontal lesions with hypercaptation of contrast significant for perilesional oedema Cerebral biopsy: granulomatous gyganto-cellular meningo-encephalitis with necrosis, probable IRIS/TB: anti-TB tretment reintroduced, still ongoing